Acticor Biotech SAS (ALACT.PA)

6.82 €

-0.08 (-1.16%)
Rating:
Recommendation:
-
Symbol ALACT.PA
Price 6.82 €
Beta 2.442
Volume Avg. 0.00M
Market Cap 71.633M
Shares () -
52 Week Range 4.5-9.389
1y Target Est -
DCF Unlevered ALACT.PA DCF ->
DCF Levered ALACT.PA LDCF ->
ROE -
ROA -
Operating Margin -
Debt / Equity 62.29% Buy
P/E -
P/B 6.49 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades


Mr. Julien Parrou
Healthcare
Biotechnology
Paris

Acticor Biotech SAS operates as a clinical stage biotechnology company that develops drugs for the treatment of acute phase of thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets a specific platelet glycoprotein. It is also involved in two clinical programs in Phase II/III registration for the treatment of ischemic stroke; and two other Phase II trials addressing major cardiovascular emergencies with clinical results expected in ischemic stroke and Covid-19 respiratory distress syndrome. The company was incorporated in 2013 and is headquartered in Paris, France.